Clinical trial No longer in our active list Phase 3 Interventional Ages 18 and up

Comparing sacituzumab tirumotecan to standard chemotherapy for advanced lung cancer

Official title: A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Run by Merck Sharp & Dohme LLC · NCT06305754 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study tests if a new drug called sacituzumab tirumotecan can help people with advanced lung cancer live longer and feel better compared to standard chemotherapy.

More Non-small Cell Lung Cancer (NSCLC) trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment520 (estimated)
SponsorMerck Sharp & Dohme LLC
Industry-sponsored
Drugs / interventionsradiation, sacituzumab, chemotherapy
Locations156 sites (Oakland, California and 155 other locations)
Trial IDNCT06305754 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals with advanced nonsquamous NSCLC who have progressed on prior EGFR tyrosine kinase inhibitors.

Probably not a fit

Patients with predominantly squamous cell histology NSCLC or those with significant peripheral neuropathy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of sacituzumab tirumotecan compared to a combination of pemetrexed and carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) who have not responded to previous EGFR tyrosine kinase inhibitors. Participants will be randomly assigned to receive either the experimental drug or the standard chemotherapy regimen. The primary goals are to assess progression-free survival and overall survival between the two treatment groups.

Why it matters

Potential benefit: If successful, this treatment could offer a more effective option for patients with advanced NSCLC who have exhausted prior therapies.

How similar studies have gone: Other studies have shown promising results with similar approaches, but this specific comparison is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC).
* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.
* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.
* Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
* Life expectancy of at least 3 months.

Exclusion Criteria:

* Predominantly squamous cell histology NSCLC.
* History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
* Grade ≥2 peripheral neuropathy.
* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
* Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.
* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
* Received radiation therapy to the lung that is \>30 Gray within 6 months of the first dose of study intervention.
* Known active central nervous system metastases and/or carcinomatous meningitis.
* Active infection requiring systemic therapy.
* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
* Concurrent active HBV and HCV infection.
* History of allogeneic tissue/solid organ transplant.
* Participants who have not adequately recovered from major surgery or have ongoing surgical complications.

Where it's running

  • Kaiser Permanente - Oakland ( Site 0054)
    Oakland, California, United States
    Recruiting
  • Kaiser Permanente - Roseville ( Site 0055)
    Roseville, California, United States
    Recruiting
  • Kaiser Permanente - San Francisco ( Site 0056)
    San Francisco, California, United States
    Recruiting
  • Kaiser Permanente - Santa Clara ( Site 0057)
    Santa Clara, California, United States
    Recruiting
  • Kaiser Permanente-Kaiser Permanente ( Site 0036)
    Vallejo, California, United States
    Recruiting
  • Kaiser Permanente - Walnut Creek ( Site 0058)
    Walnut Creek, California, United States
    Recruiting
Show 44 more locations
  • Mid Florida Hematology and Oncology Center ( Site 0005)
    Orange City, Florida, United States
    Recruiting
  • University of Michigan ( Site 0009)
    Ann Arbor, Michigan, United States
    Recruiting
  • Cox Medical Center North - Cox Medical Center/ Hematology/Medical Oncology ( Site 0051)
    Springfield, Missouri, United States
    Recruiting
  • Astera Cancer Care ( Site 0032)
    East Brunswick, New Jersey, United States
    Recruiting
  • Stony Brook University-Cancer Center ( Site 0038)
    Stony Brook, New York, United States
    Recruiting
  • Sanford Fargo Medical Center ( Site 0028)
    Fargo, North Dakota, United States
    Recruiting
  • Sanford Cancer Center ( Site 0024)
    Sioux Falls, South Dakota, United States
    Recruiting
  • John Peter Smith Hospital ( Site 0065)
    Fort Worth, Texas, United States
    Recruiting
  • University of Texas MD Anderson ( Site 0063)
    Houston, Texas, United States
    Recruiting
  • Clinica Adventista Belgrano-Oncology ( Site 0315)
    Caba., Buenos Aires, Argentina
    Recruiting
  • Instituto Alexander Fleming ( Site 0307)
    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    Recruiting
  • Hospital Británico de Buenos Aires-Oncology ( Site 0304)
    Buenos Aires, Buenos Aires F.D., Argentina
    Recruiting
  • Centro Privado de RMI Río Cuarto S.A. II ( Site 0310)
    Río Cuarto, Córdoba Province, Argentina
    Recruiting
  • Instituto de Oncología de Rosario ( Site 0301)
    Rosario, Santa Fe Province, Argentina
    Recruiting
  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0303)
    La Rioja, Argentina
    Recruiting
  • Cross Cancer Institute ( Site 0201)
    Edmonton, Alberta, Canada
    Recruiting
  • Waterloo Regional Health Network (WRHN) ( Site 0207)
    Kitchener, Ontario, Canada
    Recruiting
  • Princess Margaret Cancer Centre ( Site 0203)
    Toronto, Ontario, Canada
    Recruiting
  • McGill University Health Centre ( Site 0204)
    Montreal, Quebec, Canada
    Recruiting
  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0600)
    Bogotá, Bogota D.C., Colombia
    Recruiting
  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0606)
    Bogotá, Bogota D.C., Colombia
    Recruiting
  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0601)
    Valledupar, Cesar Department, Colombia
    Recruiting
  • IMAT S.A.S ( Site 0602)
    Montería, Departamento de Córdoba, Colombia
    Recruiting
  • Oncologos del Occidente ( Site 0604)
    Pereira, Risaralda Department, Colombia
    Recruiting
  • Fundacion Valle del Lili- CIC-Oncology CIC ( Site 0605)
    Cali, Valle del Cauca Department, Colombia
    Recruiting
  • Nouvel Hôpital Civil (NHC) ( Site 1302)
    Strasbourg, Alsace, France
    Recruiting
  • Clinique Clairval ( Site 1306)
    Marseille, Bouches-du-Rhone, France
    Recruiting
  • Hopitaux Universitaires Paris Centre-Hopital Cochin-Unité d'Oncologie Thoracique ( Site 1304)
    Paris, France
    Recruiting
  • Gustave Roussy ( Site 1303)
    Villejuif, Île-de-France Region, France
    Recruiting
  • Artemis hospital ( Site 3307)
    Gurugram, Haryana, India
    Recruiting
  • Tata Memorial Hospital-Medical Oncology ( Site 3304)
    Mumbai, Maharashtra, India
    Recruiting
  • All India Institute of Medical Sciences-Department of medical oncology ( Site 3303)
    New Delhi, National Capital Territory of Delhi, India
    Recruiting
  • Instituto Tumori Giovanni Paolo II-SSD Oncologia Medica per la Patologia Toracica ( Site 1802)
    Bari, Apulia, Italy
    Recruiting
  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1800)
    Milan, Lombardy, Italy
    Recruiting
  • Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1803)
    Milan, Lombardy, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1804)
    Florence, Tuscany, Italy
    Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
    Roma, Italy
    Recruiting
  • Fujita Health University Hospital ( Site 3409)
    Toyoake, Aichi-ken, Japan
    Recruiting
  • Ehime University Hospital ( Site 3411)
    Tōon, Ehime, Japan
    Recruiting
  • National Hospital Organization Kyushu Cancer Center ( Site 3401)
    Fukuoka, Fukuoka, Japan
    Recruiting
  • Gunma Prefectural Cancer Center ( Site 3413)
    Ōta, Gunma, Japan
    Recruiting
  • Kanazawa University Hospital ( Site 3402)
    Kanazawa, Ishikawa-ken, Japan
    Recruiting
  • St. Marianna University Hospital ( Site 3415)
    Kawasaki, Kanagawa, Japan
    Recruiting
  • Kanagawa Cancer Center ( Site 3416)
    Yokohama, Kanagawa, Japan
    Recruiting

+106 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.